Rituximab in the treatment of autoimmune haematological disorders
نویسندگان
چکیده
منابع مشابه
Rituximab in the treatment of autoimmune haematological disorders.
Current treatment regimens for haematological autoimmune diseases are relatively non-selective and are often associated with considerable toxicity. Recently, it has become clear that B cells play a key role in both the development and perpetuation of autoimmunity, suggesting that B-cell depletion could be a valuable treatment approach for patients with autoimmune diseases. This article reviews ...
متن کاملAutoimmune haematological disorders
Autoimmune diseases affect around 5% of the population but until recently, although the pathological features of these disorders could be described, there was little idea about the aetiology. Through the development of animal models and the identification of target genes some insight is being gained into the pathogenetic basis of these complex diseases. Blood disorders in which autoantibodies a...
متن کاملRituximab for the treatment of autoimmune cytopenias.
haematologica/the hematology journal | 2007; 92(12) | 1589 | Bor T-lymphocyte-mediated autoimmune disorders may lead to clinical disease characterized by low blood cell counts. The term autoimmune cytopenias has been collectively applied to this heterogeneous group of disorders. After the introduction of the humanized, chimeric monoclonal anti-CD20 antibody, rituximab, as a powerful therapeutic...
متن کاملAutoimmune haematological disorders in two Italian children with Kabuki Syndrome
Kabuki syndrome (also called Niikawa-Kuroki syndrome) is a rare genetic disease described for the first time in Japan, characterised by anomalies in multiple organ systems and often associated with autoimmune disorders and impaired immune response. We herein report the clinical history, the therapeutic approach and the outcome of two children with Kabuki syndrome who developed autoimmune haemat...
متن کاملRituximab for treatment of autoimmune hemolytic anemia.
We report the successful use of rituximab as single treatment modality in a five-month-old boy with fulminant warm autoantibody autoimmune hemolytic anemia, resistant to standard treatment. On admission, laboratory tests showed a profound anemia with a hemoglobin of 2.6 g/dL. Indirect and direct antiglobulin tests were strongly positive, and nonspecific IgG autoantibodies were detected. Two day...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2008
ISSN: 0007-1048,1365-2141
DOI: 10.1111/j.1365-2141.2008.07054.x